{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:50:29Z","timestamp":1791323429986,"version":"4.3.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Intervent Radiol"],"DOI":"10.1007\/s00270-026-04607-z","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:41:11Z","timestamp":1788986471000},"page":"1922-1934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Efficacy and Safety of Transarterial Therapies for Unresectable Neuroendocrine Liver Metastases: A Systematic Review"],"prefix":"10.1007","volume":"49","author":[{"given":"Hugo C.","family":"Temperley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Grainger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6571-6120","authenticated-orcid":false,"given":"Omar","family":"Abu Saadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niall J.","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin M.","family":"Mac Curtain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Fidelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin P.","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"issue":"10","key":"4607_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335\u201342. https:\/\/doi.org\/10.1001\/jamaoncol.2017.0589.","journal-title":"JAMA Oncol"},{"key":"4607_CR2","doi-asserted-by":"publisher","first-page":"100510","DOI":"10.1016\/j.lanepe.2022.100510","volume":"23","author":"BE White","year":"2022","unstructured":"White BE, Rous B, Chandrakumaran K, Wong K, Bouvier C, Van Hemelrijck M, et al. Incidence and survival of neuroendocrine neoplasia in England 1995\u20132018: a retrospective, population-based study. Lancet Reg Health Eur. 2022;23:100510. https:\/\/doi.org\/10.1016\/j.lanepe.2022.100510.","journal-title":"Lancet Reg Health Eur"},{"issue":"18","key":"4607_CR3","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26(18):3063\u201372. https:\/\/doi.org\/10.1200\/JCO.2007.15.4377.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4607_CR4","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","volume":"190","author":"RS Chamberlain","year":"2000","unstructured":"Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190(4):432\u201345. https:\/\/doi.org\/10.1016\/S1072-7515(00)00222-2.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"4607_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1072-7515(03)00230-8","volume":"197","author":"JM Sarmiento","year":"2003","unstructured":"Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197(1):29\u201337. https:\/\/doi.org\/10.1016\/S1072-7515(03)00230-8.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"4607_CR6","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1245\/s10434-010-1154-5","volume":"17","author":"SC Mayo","year":"2010","unstructured":"Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol. 2010;17(12):3129\u201336. https:\/\/doi.org\/10.1245\/s10434-010-1154-5.","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"4607_CR7","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1097\/01.sla.0000161981.58631.ab","volume":"241","author":"JG Touzios","year":"2005","unstructured":"Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241(5):776\u201383. https:\/\/doi.org\/10.1097\/01.sla.0000161981.58631.ab.","journal-title":"Ann Surg"},{"issue":"2","key":"4607_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"1","key":"4607_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/hpb.12326","volume":"17","author":"A Kennedy","year":"2015","unstructured":"Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski P. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17(1):29\u201337. https:\/\/doi.org\/10.1111\/hpb.12326.","journal-title":"HPB (Oxford)"},{"issue":"2","key":"4607_CR10","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1053\/j.seminoncol.2010.03.004","volume":"37","author":"J Nazario","year":"2010","unstructured":"Nazario J, Gupta S. Transarterial liver-directed therapies of neuroendocrine hepatic metastases. Semin Oncol. 2010;37(2):118\u201326. https:\/\/doi.org\/10.1053\/j.seminoncol.2010.03.004.","journal-title":"Semin Oncol"},{"issue":"2","key":"4607_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1053\/j.semnuclmed.2009.11.001","volume":"40","author":"H Ahmadzadehfar","year":"2010","unstructured":"Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40(2):105\u201321. https:\/\/doi.org\/10.1053\/j.semnuclmed.2009.11.001.","journal-title":"Semin Nucl Med"},{"issue":"2","key":"4607_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000335597","volume":"95","author":"M Pavel","year":"2012","unstructured":"Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. ENETS consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157\u201376. https:\/\/doi.org\/10.1159\/000335597.","journal-title":"Neuroendocrinology"},{"issue":"6","key":"4607_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/MPA.0b013e3181ebb2a5","volume":"39","author":"JP Boudreaux","year":"2010","unstructured":"Boudreaux JP, Klimstra DS, Hassan MM, Woltering EA, Jensen RT, Goldsmith SJ, et al. The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum. Pancreas. 2010;39(6):753\u201366. https:\/\/doi.org\/10.1097\/MPA.0b013e3181ebb2a5.","journal-title":"Pancreas"},{"issue":"7","key":"4607_CR14","doi-asserted-by":"publisher","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","volume":"19","author":"MH Shah","year":"2021","unstructured":"Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, et al. Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(7):839\u201368. https:\/\/doi.org\/10.6004\/jnccn.2021.0032.","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"4607_CR15","doi-asserted-by":"publisher","first-page":"e537","DOI":"10.3747\/co.27.6205","volume":"27","author":"E Tai","year":"2020","unstructured":"Tai E, Kennedy S, Farrell A, Jaberi A, Kachura J, Beecroft R. Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis. Curr Oncol. 2020;27(6):e537\u201346. https:\/\/doi.org\/10.3747\/co.27.6205.","journal-title":"Curr Oncol"},{"issue":"4","key":"4607_CR16","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1245\/s10434-020-09469-4","volume":"28","author":"L Ngo","year":"2021","unstructured":"Ngo L, Elnahla A, Attia AS, Hussein M, Toraih EA, Kandil E, et al. Chemoembolization versus radioembolization for neuroendocrine liver metastases: a meta-analysis comparing clinical outcomes. Ann Surg Oncol. 2021;28(4):1950\u20138. https:\/\/doi.org\/10.1245\/s10434-020-09469-4.","journal-title":"Ann Surg Oncol"},{"key":"4607_CR17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"4607_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/1471-2288-14-45","volume":"14","author":"CK Lo","year":"2014","unstructured":"Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Med Res Methodol. 2014;14:45. https:\/\/doi.org\/10.1186\/1471-2288-14-45.","journal-title":"BMC Med Res Methodol"},{"key":"4607_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"2","key":"4607_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1037","volume":"3","author":"G Salanti","year":"2012","unstructured":"Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80\u201397. https:\/\/doi.org\/10.1002\/jrsm.1037.","journal-title":"Res Synth Methods"},{"key":"4607_CR21","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","volume":"368","author":"M Campbell","year":"2020","unstructured":"Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. https:\/\/doi.org\/10.1136\/bmj.l6890.","journal-title":"BMJ"},{"issue":"3","key":"4607_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"issue":"7414","key":"4607_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"issue":"1","key":"4607_CR24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.4999\/uhod.12038","volume":"23","author":"F Ozkan","year":"2013","unstructured":"Ozkan F, Pekcevik B, Cil BE, Yurttutan N, Yalcin S, Balkanci F. Transarterial chemo and radioembolization (Yttrium90) of hepatic metastasis of neuroendocrine tumors: single center experience. Int J Hematol Oncol. 2013;23(1):20\u20137. https:\/\/doi.org\/10.4999\/uhod.12038.","journal-title":"Int J Hematol Oncol"},{"issue":"8","key":"4607_CR25","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1002\/cncr.21389","volume":"104","author":"S Gupta","year":"2005","unstructured":"Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer. 2005;104(8):1590\u2013602. https:\/\/doi.org\/10.1002\/cncr.21389.","journal-title":"Cancer"},{"issue":"7","key":"4607_CR26","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.jvir.2007.04.018","volume":"18","author":"AT Ruutiainen","year":"2007","unstructured":"Ruutiainen AT, Soulen MC, Tuite CM, Clark TWI, Mondschein JI, Stavropoulos SW, et al. Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol. 2007;18(7):847\u201355. https:\/\/doi.org\/10.1016\/j.jvir.2007.04.018.","journal-title":"J Vasc Interv Radiol"},{"issue":"5","key":"4607_CR27","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1634\/theoncologist.2010-0292","volume":"16","author":"R Whitney","year":"2011","unstructured":"Whitney R, Valek V, Fages JF, Garcia A, Narayanan G, Tatum C, et al. Transarterial chemoembolization and selective internal radiation for the treatment of patients with metastatic neuroendocrine tumors: a comparison of efficacy and cost. Oncologist. 2011;16(5):594\u2013601. https:\/\/doi.org\/10.1634\/theoncologist.2010-0292.","journal-title":"Oncologist"},{"issue":"4","key":"4607_CR28","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1159\/000336941","volume":"96","author":"F Maire","year":"2012","unstructured":"Maire F, Lombard-Bohas C, O\u2019Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: a prospective randomized study. Neuroendocrinology. 2012;96(4):294\u2013300. https:\/\/doi.org\/10.1159\/000336941.","journal-title":"Neuroendocrinology"},{"issue":"2","key":"4607_CR29","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/MPA.0000000000000030","volume":"43","author":"ES Engelman","year":"2014","unstructured":"Engelman ES, Leon-Ferre R, Naraev BG, Sharma N, Sun S, O\u2019Dorisio TM, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution. Pancreas. 2014;43(2):219\u201325. https:\/\/doi.org\/10.1097\/MPA.0000000000000030.","journal-title":"Pancreas"},{"issue":"1","key":"4607_CR30","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","volume":"47","author":"F Fiore","year":"2014","unstructured":"Fiore F, Del Prete M, Franco R, Marotta V, Ramundo V, Marciello F, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine. 2014;47(1):177\u201382. https:\/\/doi.org\/10.1007\/s12020-013-0130-9.","journal-title":"Endocrine"},{"issue":"9","key":"4607_CR31","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jvir.2016.05.014","volume":"27","author":"MS Makary","year":"2016","unstructured":"Makary MS, Kapke J, Yildiz V, Pan X, Dowell JD. Conventional versus drug-eluting bead transarterial chemoembolization for neuroendocrine tumor liver metastases. J Vasc Interv Radiol. 2016;27(9):1298\u2013304. https:\/\/doi.org\/10.1016\/j.jvir.2016.05.014.","journal-title":"J Vasc Interv Radiol"},{"issue":"1","key":"4607_CR32","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/ajco.12438","volume":"12","author":"M Pericleous","year":"2016","unstructured":"Pericleous M, Caplin ME, Tsochatzis E, Yu D, Morgan-Rowe L, Toumpanakis C. Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes. Asia Pac J Clin Oncol. 2016;12(1):61\u20139. https:\/\/doi.org\/10.1111\/ajco.12438.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"4607_CR33","doi-asserted-by":"publisher","first-page":"441","DOI":"10.21037\/jgo.2016.02.02","volume":"7","author":"S Singla","year":"2016","unstructured":"Singla S, LeVea CM, Pokuri VK, Attwood KM, Wach MM, Tomaszewski GM, et al. Ki67 score as a potential predictor in the selection of liver-directed therapies for metastatic neuroendocrine tumors: a single institutional experience. J Gastrointest Oncol. 2016;7(3):441\u20138. https:\/\/doi.org\/10.21037\/jgo.2016.02.02.","journal-title":"J Gastrointest Oncol"},{"issue":"1","key":"4607_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s00270-016-1478-z","volume":"40","author":"JX Chen","year":"2017","unstructured":"Chen JX, Rose S, White SB, El-Haddad G, Fidelman N, Yarmohammadi H, et al. Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival. Cardiovasc Intervent Radiol. 2017;40(1):69\u201380. https:\/\/doi.org\/10.1007\/s00270-016-1478-z.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"12","key":"4607_CR35","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1007\/s00330-017-4856-2","volume":"27","author":"D Do Minh","year":"2017","unstructured":"Do Minh D, Chapiro J, Gorodetski B, Huang Q, Liu C, Smolka S, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995\u20135005. https:\/\/doi.org\/10.1007\/s00330-017-4856-2.","journal-title":"Eur Radiol"},{"issue":"2","key":"4607_CR36","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1007\/s00268-017-4324-9","volume":"42","author":"AK Elf","year":"2018","unstructured":"Elf AK, Andersson M, Henrikson O, Jalnefjord O, Ljungberg M, Svensson J, et al. Radioembolization versus bland embolization for hepatic metastases from small intestinal neuroendocrine tumors: short-term results of a randomized clinical trial. World J Surg. 2018;42(2):506\u201313. https:\/\/doi.org\/10.1007\/s00268-017-4324-9.","journal-title":"World J Surg"},{"issue":"4","key":"4607_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jamcollsurg.2019.12.026","volume":"230","author":"ME Egger","year":"2020","unstructured":"Egger ME, Armstrong E, Martin RCG 2nd, Scoggins CR, Philips P, Shah M, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg. 2020;230(4):363\u201370. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2019.12.026.","journal-title":"J Am Coll Surg"},{"issue":"12","key":"4607_CR38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.hpb.2024.08.011","volume":"26","author":"SM Ruff","year":"2024","unstructured":"Ruff SM, Chang JY, Xu M, Ejaz AM, Dillhoff M, Pawlik TM, et al. Trans-arterial embolization versus chemoembolization for neuroendocrine liver metastases: a propensity matched analysis. HPB (Oxford). 2024;26(12):1505\u201314. https:\/\/doi.org\/10.1016\/j.hpb.2024.08.011.","journal-title":"HPB (Oxford)"},{"issue":"12","key":"4607_CR39","doi-asserted-by":"publisher","first-page":"e250298","DOI":"10.1530\/ERC-25-0298","volume":"32","author":"AL Vedie","year":"2025","unstructured":"Vedie AL, Matteini F, Cros J, Dioguardi Burgio M, Gregory J, Hentic O, et al. Chemoembolization using streptozotocin versus embolization in metastatic NETs. Endocr Relat Cancer. 2025;32(12):e250298. https:\/\/doi.org\/10.1530\/ERC-25-0298.","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"4607_CR40","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s13063-018-2782-5","volume":"19","author":"JX Chen","year":"2018","unstructured":"Chen JX, Wileyto EP, Soulen MC. Randomized embolization trial for neuroendocrine tumor metastases to the liver (RETNET): study protocol for a randomized controlled trial. Trials. 2018;19(1):390. https:\/\/doi.org\/10.1186\/s13063-018-2782-5.","journal-title":"Trials"},{"issue":"6","key":"4607_CR41","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.jvir.2008.01.030","volume":"19","author":"T de Baere","year":"2008","unstructured":"de Baere T, Deschamps F, Teriitheau C, Rao P, Conengrapht K, Schlumberger M, et al. Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol. 2008;19(6):855\u201361. https:\/\/doi.org\/10.1016\/j.jvir.2008.01.030.","journal-title":"J Vasc Interv Radiol"},{"issue":"3","key":"4607_CR42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00270-011-0122-1","volume":"34","author":"SK Gaur","year":"2011","unstructured":"Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, et al. Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Intervent Radiol. 2011;34(3):566\u201372. https:\/\/doi.org\/10.1007\/s00270-011-0122-1.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"2","key":"4607_CR43","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00270-012-0424-y","volume":"36","author":"N Bhagat","year":"2013","unstructured":"Bhagat N, Reyes DK, Lin M, Kamel I, Pawlik TM, Frangakis C, et al. Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol. 2013;36(2):449\u201359. https:\/\/doi.org\/10.1007\/s00270-012-0424-y.","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"4607_CR44","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-Fabrega J, Burrel M, Garcia-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"issue":"1","key":"4607_CR45","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["CardioVascular and Interventional Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00270-026-04607-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00270-026-04607-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T21:00:27Z","timestamp":1791320427000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00270-026-04607-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":45,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4607"],"URL":"https:\/\/doi.org\/10.1007\/s00270-026-04607-z","relation":{},"ISSN":["1432-086X"],"issn-type":[{"value":"1432-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"15 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Institutional Review Board approval was not required for this systematic review of previously published data.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, consent for publication is not required.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"For this type of study, informed consent is not required.","order":4,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}